By George Ongkojoyo 
A multi-institutional team of Canadian researchers has successfully demonstrated a revolutionary approach to precision oncology, integrating advanced protein analysis with rapid biological modeling to identify life-extending treatments for pediatric patients with rare, resistant cancers. Led by scientists from the University of British Columbia (UBC) and the BC Children’s Hospital Research Institute (BCCHR), the study marks the first time in Canada that proteomics—the large-scale study of proteins—has been combined with "avatar" modeling in chicken eggs to guide real-time clinical decision-making for a young oncology patient.
The findings, published today in the journal EMBO Molecular Medicine, represent a significant shift in the landscape of personalized medicine. While genomic sequencing has long been the gold standard for identifying targetable mutations in cancer, this new research highlights a critical gap: genes provide the blueprints, but proteins are the functional machines that drive tumor growth. By focusing on the "machinery" rather than just the "blueprints," the team identified a metabolic vulnerability in a rare pediatric tumor that had previously baffled traditional diagnostic methods.
The Limitations of Genomic-Centric Oncology
For decades, the push toward precision medicine has been synonymous with genomics. By sequencing a patient’s DNA, doctors hope to find specific mutations that can be targeted by existing drugs. However, for many young patients with rare or aggressive cancers, genomic testing often yields no actionable results, or the identified targets do not respond to treatment as expected.
In the case detailed in the new study, an unnamed pediatric patient was diagnosed with a rare cancer that proved resistant to conventional chemotherapy. When the medical team performed standard genomic sequencing, they initially identified a potential drug candidate. However, the tumor quickly developed resistance to that medication. Subsequent genetic testing offered no further clear paths for intervention, leaving the clinical team with few options.
"With genomics alone, we couldn’t find a clear treatment option," explained Dr. Philipp Lange, a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR and an associate professor at UBC. "Genomics tells us what might happen based on the genetic code, but it doesn’t always reflect what is actually happening in the cell at a functional level."
Proteomics: Identifying the Functional Vulnerability
To break the diagnostic deadlock, the research team turned to proteomics. Unlike genomics, which looks at the instructions for building a cell, proteomics analyzes the proteins themselves—the molecules that carry out nearly all biological functions and are the primary targets for most drugs.
The study, co-led by postdoctoral researcher Dr. Georgina Barnabas and PhD student Tariq Bhat, utilized high-resolution mass spectrometry to profile the protein landscape of the patient’s resistant tumor. This deep dive revealed that the tumor’s metabolism was heavily dependent on an enzyme called SHMT2 (serine hydroxymethyltransferase 2). This enzyme plays a pivotal role in one-carbon metabolism, a pathway that provides the building blocks necessary for rapid cancer cell division and survival.
The identification of SHMT2 provided a "hidden" target that genomic sequencing had missed. Because the tumor was over-relying on this specific metabolic pathway, the researchers hypothesized that inhibiting SHMT2 could effectively "starve" the cancer cells of the energy and materials they needed to proliferate.
The Chicken Egg Avatar: A Race Against Time
Identifying a potential protein target is only half the battle; clinicians must also prove that a drug can safely and effectively inhibit that target in a living system before administering it to a patient. In pediatric oncology, where time is of the essence, traditional animal models—such as mice—are often too slow. It can take several months to successfully graft a human tumor into a mouse and test various drug responses, a timeline that many critically ill children do not have.
To solve this, the team utilized an innovative "avatar" host: the chicken egg. Through the BRAvE initiative (Better Responses through Avatars and Evidence) at BCCHR, researchers used the chorioallantoic membrane (CAM) of the chicken egg to grow small samples of the patient’s tumor.
"This technique speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," said Dr. James Lim, a senior investigator at BCCHR and associate professor at UBC. "By growing the patient’s specific tumor on the egg’s vascular membrane, we created a living model that allowed us to test drug responses in a matter of weeks rather than months."
The researchers tested sertraline, a common antidepressant and SSRI, on the egg-grown tumors. Previous biochemical research had suggested that sertraline possesses the secondary property of inhibiting SHMT2. The results in the egg avatars were definitive: the drug successfully inhibited the enzyme and slowed the growth of the patient’s tumor.
A Chronology of Precision Intervention
The timeline of the intervention illustrates the efficiency of this integrated approach. After the failure of standard care and the emergence of genomic resistance, the proteomics and avatar testing were initiated.
- Tumor Sampling: A biopsy of the resistant tumor was taken and split between protein analysis and avatar grafting.
- Proteomic Profiling: Mass spectrometry identified the SHMT2 enzyme as a critical metabolic bottleneck.
- Avatar Testing: Within two weeks, the tumor samples were established in chicken eggs. Sertraline was applied to the grafts, and researchers observed a measurable reduction in tumor progression.
- Expert Review: The findings were presented to a national panel of experts through PROFYLE (PRecision Oncology For Young peopLE). The panel reviewed the molecular evidence and the avatar data, ultimately recommending sertraline as the most viable experimental treatment for the patient.
- Clinical Administration: The patient began treatment with sertraline. While the drug did not provide a total cure, it succeeded in slowing the growth of a previously rampant and resistant cancer, providing the clinical team with precious time to explore further therapeutic avenues.
The Collaborative Framework: PROFYLE and ACCESS
The success of this study was made possible by a robust national infrastructure designed to tackle the most difficult cases of childhood cancer. PROFYLE is a key initiative of the Canadian pediatric cancer network known as ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship).
ACCESS brings together more than 30 research and funding organizations, alongside over 100 investigators across Canada. This network ensures that a child in Vancouver can benefit from the same level of specialized molecular analysis and expert consultation as a child in Toronto or Halifax. By pooling resources and data, PROFYLE aims to move beyond the "one-size-fits-all" approach to oncology, focusing specifically on children and young adults who have a less than 20 percent chance of survival with conventional treatments.
The involvement of the Michael Cuccione Childhood Cancer Research Program further highlights the role of philanthropic and community support in driving high-risk, high-reward medical innovation.
Broader Implications and Future Directions
The implications of this study reach far beyond a single patient case. It serves as a successful "proof of concept" for the integration of proteomics into the clinical workflow. While genomic testing is becoming more common, proteomics remains largely confined to the research lab. This study demonstrates that with the right infrastructure, protein analysis can be performed quickly enough to influence bedside decisions.
Furthermore, the use of chicken egg avatars addresses a major hurdle in personalized medicine: the need for functional validation. Simply knowing a target exists is not the same as knowing a drug will work. The egg model provides a rapid, cost-effective, and biologically relevant platform for testing "off-label" drug uses, such as using an antidepressant to treat a metabolic vulnerability in cancer.
"While there is more work to be done, this study shows that our approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers," said Dr. Lange. "Our goal now is to standardize and expand this method. We want to ensure that every child in Canada facing a resistant cancer has access to this level of deep molecular and functional analysis."
Conclusion: A New Standard for Pediatric Oncology
The pan-Canadian team’s work underscores a growing consensus in the scientific community: the future of oncology lies in multi-omic integration. By combining the "what" of genomics with the "how" of proteomics and the "if" of functional avatar testing, researchers are providing a more holistic and actionable view of cancer than ever before.
For the young patients and families navigating the complexities of rare cancers, this research offers a new sense of hope. It suggests that even when the genetic roadmap fails, the answers may still be found within the functional machinery of the tumor itself, waiting to be uncovered by the next generation of diagnostic tools. As the researchers at UBC and BC Children’s Hospital continue to refine these techniques, the transition from experimental success to standard clinical practice appears increasingly within reach.